KemPharm (NASDAQ:KMPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “
Separately, ValuEngine raised KemPharm from a “strong sell” rating to a “sell” rating in a research note on Monday, October 23rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $8.15.
Shares of KemPharm (NASDAQ:KMPH) remained flat at $$5.00 during mid-day trading on Wednesday. 76,446 shares of the stock traded hands, compared to its average volume of 52,272. KemPharm has a 1 year low of $2.45 and a 1 year high of $5.40. The company has a debt-to-equity ratio of -1.92, a quick ratio of 7.56 and a current ratio of 7.56.
In other news, EVP Daniel L. Cohen purchased 7,500 shares of the business’s stock in a transaction dated Monday, November 27th. The shares were purchased at an average cost of $3.79 per share, with a total value of $28,425.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 22.80% of the company’s stock.
An institutional investor recently raised its position in KemPharm stock. C WorldWide Group Holding A S increased its stake in KemPharm, Inc. (NASDAQ:KMPH) by 14.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 435,528 shares of the specialty pharmaceutical company’s stock after acquiring an additional 53,829 shares during the quarter. C WorldWide Group Holding A S owned about 2.97% of KemPharm worth $1,611,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 36.04% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “KemPharm (KMPH) Downgraded to “Hold” at Zacks Investment Research” was first published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thestockobserver.com/2018/01/14/kempharm-kmph-downgraded-to-hold-at-zacks-investment-research.html.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.